Cognoa and Eversana announced a partnership to advance the industry standard by which digital medicines will be ordered, dispensed, and covered by insurance.
Mallinckrodt plc agreed to sell the global biopharmaceutical company’s wholly owned subsidiary BioVectra Inc. to an affiliate of private equity investment firm H.I.G. Capital for $250 million.
Neurotrope Inc.’s shares tumbled nearly 80 percent after the company said the drug developer’s experimental Alzheimer’s disease treatment Bryostatin-1 did not meet the main goal of a mid-stage study.
Syneos Health showcased Syneos Health Deployment Solutions at the Future Pharma Conference in Boston. Advancing the traditional outsourced field sales model, Deployment Solutions delivers a customized, integrated mix of promotional and educational channels purposefully designed to ensure successful commercialization.
Lilly’s targeted RET drug shrinks tumors in lung cancer trial
Acquisitions, Advanced lung cancer, Business, Clinical Trials, European Society for Medical Oncology (ESMO), FDA, Gene Abnormalities, Liver Enzymes, Non-Small Cell Lung Cancer, Papillary Thyroid Cancer, R&D, RET Gene, Tumor Shrinkage, Tumors, World Conference on Lung CancerEli Lilly and Co.’s LOXO-292, an experimental cancer drug the company acquired in January 2019 as part of an $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70 percent of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.
The owner of a telemarketing company implicated in the largest component of a $1.2 billion Medicare fraud involving the supply of medically unnecessary orthotic braces pleaded guilty to criminal charges, the U.S. Department of Justice said.
AstraZeneca struck a deal to use Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.
Danish drugmaker Novo Nordisk will offer cheaper insulin to U.S. diabetics in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly.
Nearly one year after charges were filed against former Genentech employees accused of stealing trade secrets to benefit Taiwan-based biosimilar drugmaker JHL Biotech, the two companies reached an agreement over the ill-gotten intellectual property – destruction.
Sumitomo Dainippon Pharma and Roivant Sciences Create Broad Strategic Alliance for New Medicines
Alliances, Biopharmaceutical, Business, Drug Distribution, Market Access, Market exclusivity, New Medicines, Pediatric Rare Diseases, Prostate Cancer, Respiratory Disease, Stakes, Urinary Diseases, Women’s HealthThe Sumitomo Dainippon-Roivant Alliance encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and Digital Innovation.
